• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Varenicline Effective for Alcohol Use Disorder?

Is Varenicline Effective for Alcohol Use Disorder?

May 1, 2018
Thomas Jordan, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD. Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: O’Malley S et al, JAMA Psychiatry 2018;75(2):129–138

Acting on the nicotinic acetylcholine receptors, varenicline (Chantix) is an FDA-approved treatment for smoking cessation. These receptors are implicated in both nicotine and alcohol reward pathways, so could varenicline also be helpful for treating alcohol use disorder (AUD)? So far, the evidence has been mixed, but some studies have shown a greater benefit of varenicline in those who use both alcohol and cigarettes, compared to those who just use alcohol.

This 16-week study was a phase 2, randomized, double-blind, placebo-controlled trial comparing the effects of varenicline and medical management to medical management plus placebo for treatment of AUD. The 131 participants recruited (including 39 women) met DSM-IV-TR criteria for alcohol dependence and smoked at least 2 days a week. The intervention group was given varenicline titrated up to 1 mg twice a day, and both groups were seen for 12 medical management sessions for AUD, which is a behavioral intervention used by medical professionals to support medication adherence (4 sessions) and use strategies for achieving drinking goals (8 sessions).

The primary outcomes were reduction in drinking by percentage of heavy drinking days (PHDD) and no heavy drinking days (NHDD), defined as ≥ 5 standard drinks a day for men or ≥ 4 for women. One standard drink equaled a 12-ounce beer with an alcohol content of 5%, 5 ounces of wine (12% alcohol), or 1.5 ounces of distilled spirits (40% alcohol). Secondary outcomes were prolonged abstinence (28 days) from smoking, confirmed by plasma cotinine levels < 6 ng/mL.

The results of the primary outcome, PHDD, showed no significant difference in the overall sample between those on varenicline or placebo. However, there was a significant difference between the response of men and women in the study. PHDD in men showed a greater (but still non-significant) reduction than women, and the NHDD in men was nearly significant—29% on varenicline had NHDD vs 6% for placebo (95% CI, 0.22–1.03). Smoking outcomes showed a significant difference in prolonged abstinence from smoking for those on varenicline—13% vs 0% (P = .003). The only significantly different side effect was more abnormal dreaming in the varenicline group (43.8% vs 22.4%), which was experienced more often by women than men—women taking varenicline were 35% more likely than men to report this complaint.

Three adverse events happened in the varenicline group: an admission to alcohol rehabilitation, a hospitalization for suicidal ideation, and another hospitalization for blood pressure monitoring. Two adverse events happened with placebo: psychiatric hospitalization in one, and hospitalization for an infection in another. Women on varenicline were more likely to report abnormal dreams and to reduce or discontinue the medication than either men or women on placebo.

CATR’s Take
While the results are not robust, they point to a greater benefit in men with AUD than in women. However, the small number of women in the study limits this conclusion, and it could be that women don’t tolerate treatment doses of varenicline as well. More research is needed to look into these differences. Another take-home point is that, even without any other smoking cessation interventions, varenicline helped with prolonged abstinence from smoking.
Addiction Treatment
KEYWORDS addiction psychopharmacology_tips research-update substance-abuse
    Thomas Jordan, MD.

    Methylphenidate Max Dosing

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Pain and Addiction, CATR May/June 2018
    Treating Chronic Pain When There’s Addiction: A Primer
    Assessing and Treating Psychogenic Pain
    Using Caution While Prescribing Opioids for Pain
    Prevalence of Fetal Alcohol Spectrum Disorder
    Is Varenicline Effective for Alcohol Use Disorder?
    Guidelines for Switching From Methadone to Buprenorphine
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.